A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Conditions:   Polymyositis;   Dermatomyositis Interventions:   Drug: Ustekinumab 6 mg/kg;   Drug: Ustekinumab 90 mg;   Drug: Placebo IV;   Drug: Placebo SC Sponsor:   Janssen Pharmaceutical K.K. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials